Assist. Prof. Dr. Golnar Rahimzadeh | Infectious Diseases | Best Researcher Award
Mazandaran University of Medical Sciences | Iran
Assist. Prof. Dr. Golnar Rahimzadeh is an Iranian scientist and Assistant Professor at the Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences. She specializes in bacteriophage therapy, antimicrobial resistance, and pediatric infectious diseases. Her contributions span both academia and biotechnology, where she bridges microbiology with pharmaceutical innovation. She established a knowledge-based company, Persian Nano-Bio Therapy, focusing on bacteriophage therapeutics. Through her research, teaching, and entrepreneurial activities, Assist. Prof. Dr. Golnar Rahimzadeh continues to advance innovative strategies against resistant pathogens, strengthening biomedical research and global health.
Professional Profile
Scopus
Orcid
Education
Assist. Prof. Dr. Golnar Rahimzadeh completed her undergraduate studies at Islamic Azad University, Isfahan, and pursued a master’s in microbiology at Islamic Azad University, Tehran. She later obtained her doctorate in medical sciences from Mazandaran University of Medical Sciences, focusing on bacteriophage-based therapeutics, followed by a postdoctoral fellowship where she expanded her expertise in pediatric infectious diseases, microbial resistance, and nano-phage applications.
Experience
Assist. Prof. Dr. Golnar Rahimzadeh has professional experience in clinical laboratories, stem cell technology, and infectious disease research. She contributed to laboratory diagnostics, stem cell banking, HLA typing, and flow cytometry before joining Mazandaran University of Medical Sciences as Assistant Professor. She manages research laboratories, supervises academic projects, and organizes scientific congresses, demonstrating strong leadership in translational medicine, biomedical innovation, and interdisciplinary research collaborations.
Awards
Assist. Prof. Dr. Golnar Rahimzadeh is distinguished for her academic excellence and innovation in biomedical research. She co-founded Persian Nano-Bio Therapy, a knowledge-based biotechnology company advancing bacteriophage-based therapeutics. Her appointment as Assistant Professor reflects her scholarly impact, while her entrepreneurial success demonstrates her ability to translate microbiological research into practical healthcare solutions, positioning her as a pioneer in phage therapy and antimicrobial resistance.
Research Interests
Assist. Prof. Dr. Golnar Rahimzadeh focuses on bacteriophage therapy, antimicrobial resistance, pediatric infectious diseases, and microbial pathogenesis. She investigates nano-encapsulation strategies, phage-based disinfectants, and bacteriophage applications against resistant pathogens. Her work includes laboratory experiments, clinical studies, and systematic reviews. She aims to translate innovative research into sustainable treatments, integrating microbiology, biotechnology, and clinical medicine to address urgent healthcare challenges in infectious disease management.
Publication Top Notes
Title: Multi‐state evaluation of Candida infections in burn patients
Year: 2024
Title: Aloe vera Nanofibers Contained Pseudomonas Bacteriophages Fabrication, Characterization, and Biofunction
Year: 2022
Title: Potential of lytic bacteriophages as disinfectant to control of Pseudomonas aeruginosa on fomites
Year: 2022
Title: Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran
Year: 2022
Title: Encapsulation of bacteriophage cocktail into chitosan for the treatment of bacterial diarrhea
Year: 2021
Conclusion
Assist. Prof. Dr. Golnar Rahimzadeh exemplifies academic excellence and biomedical innovation. Her pioneering contributions in bacteriophage therapy and antimicrobial resistance highlight her dedication to advancing healthcare solutions. Through her leadership at Mazandaran University of Medical Sciences and her role in Persian Nano-Bio Therapy, she continues to shape innovative strategies against resistant infections, strengthening translational research and contributing to global public health advancements.